Jose-Javier Sanz-Lacalle

Learn More
PURPOSE To determine the tolerability of capecitabine in elderly patients with advanced colorectal cancer (CRC). PATIENTS AND METHODS Fifty-one patients with advanced CRC who were >/= 70 years and considered ineligible for combination chemotherapy received oral capecitabine 1,250 mg/m(2) twice daily on days 1 to 14 every 3 weeks. Patients with a(More)
3567 Background: X has superior efficacy and improved safety compared to bolus 5-FU/LV in 1st line MCRC and preserves its safety advantage in pts >65 in the adjuvant setting. We investigated its use in an elderly pt population. METHODS Objectives were to determine efficacy and safety of twice daily oral X as 1st line therapy in elderly pts with(More)
  • 1